196194-97-5

Basic information

• Product Name: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide
• Synonyms: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide
• CAS NO: 196194-97-5
• Molecular Formula: C₁₀H₁₂N₂O₄
• Molecular Weight: 224.21328
• Mol File: 196194-97-5.mol

Chemical Properties

• Boiling Point: 423.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.283±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 13.62±0.70(Predicted)
• CAS DataBase Reference: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(196194-97-5)
• EPA Substance Registry System: N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetaMide(196194-97-5)

Safety Data

• Hazardous Substances Data: 196194-97-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetamide serves as an intermediate in the synthesis of pharmaceutical drugs and organic compounds. Its presence in the development process is crucial for creating a range of medicinal products.
Used as an Analgesic:
Leveraging its analgesic properties, N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetamide is utilized for the management of pain. Its capacity to alleviate discomfort makes it a beneficial component in pain relief formulations.
Used as an Anti-Inflammatory Agent:
This chemical compound is also recognized for its anti-inflammatory properties, making it a potential candidate for treating conditions characterized by inflammation.
Used in Medical Research:
N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetamide has been studied for its potential use in treating various medical conditions, indicating its importance in ongoing scientific investigations and drug discovery efforts.
Overall, N-(4-Methoxy-2-Methyl-5-nitrophenyl)acetamide is an important chemical with diverse applications in the pharmaceutical and chemical industries, underscoring its significance in both the development of new drugs and the advancement of scientific knowledge.

Upstream product

• 31601-41-9 N-(4-methoxy-2-methylphenyl)acetamide 
• 7646-78-8 tin(IV) chloride 
• 102-50-1 2-methyl-4-methoxyaniline 

Downstream Products

• 1378949-53-1 methyl 2-acetamido-4-(2-acetamido-4-(2-acetamido-5-methoxy-4-nitrobenzamido)-5-methoxybenzamido)-5-methoxybenzoate 
• 1378949-50-8 methyl 2-acetamido-4-(2-acetamido-4-(2-amino-5-methoxy-4-nitrobenzamido)-5-methoxybenzamido)-5-methoxybenzoate hydrochloride 
• 1378949-48-4 methyl 2-acetamido-4-(2-acetamido-4-amino-5-methoxybenzamido)-5-methoxybenzoate 
• 1378949-47-3 methyl 2-acetamido-5-methoxy-4-(5-methoxy-4-nitro-2-(2-phenylacetamido)benzamido)benzoate 
• 1378949-46-2 methyl 2-acetamido-5-methoxy-4-(5-methoxy-2-(3-methylbutanamido)-4-nitrobenzamido)benzoate 
• 1378949-39-3 2-amino-5-methoxy-4-nitrobenzoic acid hydrochloride 
• 1378949-37-1 methyl 2-acetamido-4-amino-5-methoxybenzoate 
• 875155-09-2 methyl 2-acetamido-5-methoxy-4-nitrobenzoate 
• 196194-98-6 2-acetamido-5-methoxy-4-nitrobenzoic acid 
• 854908-04-6 4-Amino-5-methyl-2-nitro-phenol 
• 123343-96-4 4-methoxy-2-methyl-5-nitroaniline 
• 196194-99-7 2-amino-5-methoxy-4-nitrobenzoic acid 
• 5349-76-8 2,4-diamino-1-methoxy-5-methyl-benzene 
• 196195-00-3 6-methoxy-7-nitro-3,4-dihydroquinazolin-4-one 

Relevant articles and documents

Substituted quinolinone inhibitor

The invention provides a substituted quinolinone inhibitor and relates to a compound as shown in a formula (II) which is described in the specification or a pharmaceutically acceptable salt, solvate,active metabolite, polymorphic substance, ester, isomer or prodrug thereof, a pharmaceutical composition containing the compound as shown in the formula (II), and application of the compound and the pharmaceutical composition to treatment of diseases related to abnormal TOPK activity.

Phenyl [...] compound and its preparation method, pharmaceutical composition, drug use (by machine translation)

The invention provides a phenylurea coupling quinazoline compound or a pharmaceutically acceptable salt thereof represented by formula (I), wherein R1 represents H, represents Br, Cl or F, represents -CH3, -CH2-CH3, -CH2(CH3)2 or -CF3, represents -O-CH3, -O-CH2-CH3 or -O-CH2(CH3)2, or represents -C[triple bond]CH or -C[triple bond]N; n1 is 1, 2, 3, 4 or 5; one of R2 and R3 is a group represented by formula (II); R4 represents H, represents Br, Cl or F, represents -CH3, -CH2-CH3, -CH2(CH3)2 or -CF3, represents -O-CH3, -O-CH2-CH3 or -O-CH2(CH3)2, represents -NH2, or represents -NO2; n2 is 1, 2, 3, 4 or 5; and the other one of R2 and R3 represents H, -O-CH3, -O-CH2-CH3, -O-CH2(CH3)2, or the following groups.

Double-sided α-helix mimetics

The design and synthesis of substituted bis- and tris-benzamides is reported in which the projection of side-chain residues on both sides of an α-helix is reproduced. The scaffold is conformationally constrained by a series of intramolecular hydrogen bonds, allowing for spatial and angular mimicry of the i, i+2, i+4 and i+6 side-chains in the case of the bis-benzamide, and may be extended to higher-order oligomers.

UREA-SUBSTITUTED AND URETHANE-SUBSTITUTED ACYLUREAS, METHODS FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS

The invention relates to urea-substituted and urethane-substituted acylureas, to physiologically compatible salts thereof and to their physiologically functional derivatives. The invention thus relates to compounds of formula (I), wherein the radicals have the cited meanings. The invention also relates to the physiologically compatible salts of these compounds and to methods for the production thereof. The inventive compounds are suited for use, for example, as antidiabetics.

Quinazoline derivatives as VEGF inhibitors

The invention relates to quinazoline derivatives of formula (I) STR1wherein: Z represents --O--, --NH-- or --S--; m is an integer from 1 to 5; R 1 represents hydrogen, hydroxy, halogeno, nitro, trifluorometlyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio or NR 5 R 6 (wherein R 5 and R 6, which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, halogeno, methoxy, amino, or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X 1 represents --O--, --CH 2 --, --S--, --SO--, SO 2 --, --NR 6 --, NR 8 CO--, --CONR 9 --SO 2 NR 10 -- or --NR 11 SO 2 --, (wherein R 7, R 8, R 9, R 10 and R 11 each represents C 1-3 alkyl, C 1-3 alkoxyC 2-3 alkyl); R 4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocylic or heterocyclic group; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient the compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.